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Summary This study aimed to assess the proportion of patients with advanced breast cancer who report benefit from first-line palliative
chemotherapy using a simple global measure of wellbeing and to identify factors predicting benefit. A consecutive series of women with
advanced breast cancer undergoing first-line palliative chemotherapy was evaluated. The main outcome measure was patient report of
overall wellbeing assessed at post-treatment interview. Physical, psychological and functional status were assessed using the Rotterdam
Symptom Checklist (RSCL) on three occasions (pretreatment, at the start of the third cycle and post treatment). It was planned that treatment
would be discontinued after six cycles (i.e. 18-24 weeks). One hundred and sixty patients started treatment, of whom 155 were assessable
for quality of life. After treatment, 41 (26%) patients reported they felt better, 29 (19%) felt the same and 34 (22%) felt worse than they did
before treatment. The other 51 (33%) patients either died or stopped attending the hospital before the post-treatment interview and were
assigned as treatment 'failures'. Patients who reported feeling better after treatment had improvements in psychological distress (P< 0.0001),
pain (P = 0.01), lack of energy (P = 0.02) and tiredness (P = 0.02), as well as improvement in functional status (P = 0.07). Feeling better was
also correlated with disease response (P = 0.03). Feeling worse after treatment or treatment 'failure' was predicted by the pretreatment
presence of a dry mouth (P = 0.003) and high levels of psychological distress (P = 0.03). Pretreatment lack of energy (P = 0.01), dry mouth
(P = 0.02), presence of liver metastases (P = 0.03) and breathlessness (P = 0.03) predicted treatment 'failures'. The results of this study
suggest that first-line palliative chemotherapy for advanced breast cancer confers benefit on a substantial proportion of patients, with about
one-quarter feeling better after treatment and nearly a half feeling better or the same some 4-6 months after the start of treatment. Factors
identified in this study may assist clinicians in deciding which patients should not be offered treatment, because of high risk of feeling worse
or treatment 'failure'. This work now needs to be validated on a further cohort of women receiving chemotherapy for advanced breast cancer.
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Chemotherapy has been used widely in the management of
patients with advanced breast cancer for over 20 years. When it
was introduced, no randomized trials were undertaken to compare
the benefits of chemotherapy with the best supportive care in
terms of survival or quality of life. Disease response measured in
terms of tumour shrinkage was, however, observed relatively
frequently and this has been shown to be associated with relief of
symptoms and improvement in quality of life (Baum et al, 1980).
In a few individual cases, chemotherapy probably prolongs
survival by months or even years.
If chemotherapy was without toxicity, these benefits would
almost certainly be considered worthwhile, even if they were
only experienced by a small proportion of patients. The problem
associated with making recommendations regarding the use
of chemotherapy is that a considerable proportion of patients
experience toxicity without gaining any benefits.
Chemotherapy is given for a range of reasons (Rubens et al,
1992; Maher et al, 1994). These include reliefof symptoms, delay
orprevention ofanticipated problems and possible prolongation of
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life. Treatment is sometimes given more in hope than expectation
ofbenefit. Situations exist in which there is pressure on a clinician
to use chemotherapy as a substitute for more appropriate support
(Maher et al, 1994). The overall aim of giving chemotherapy to
patients with advanced breast cancer should be to optimize
patients' quality oflife.
A small number of recently conducted randomized controlled
trials comparing different chemotherapy regimens in the treatment
of advanced breast cancer have included quality of life as an
outcome measure (Coates et al, 1987; Tannock et al, 1988;
Richards et al, 1992; Fraser et al, 1993). These have yielded
important information about patient-reported benefit from treat-
ment. The wider application of the results of these trials to the
many clinical circumstances affecting patients with advanced
breast cancer is, however, limited by the fact that the patients
entered into such trials are not likely to be representative ofall the
patients the clinician sees. Many patients are not suitable for entry
into a clinical trial, forexample because they are too ill orrefuse to
give informed consent or are ineligible from a variety ofrestrictive
selection criteria. A number ofstudies have suggested that patients
entered into clinical trials have a better prognosis than those who
are not (Maher, 1992). A clearer appreciation of the impact on
quality oflife ofpalliative chemotherapy given to all patients with
advanced breast cancer (whether in the context of a trial or
empirically) should facilitate clinical decision making in this
controversial area.
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The main aim of this study was to define the proportion of
patients who report benefit from first-line palliative chemotherapy
in a consecutive series ofwomen with advanced breast cancer. The
second aim was to attempt to identify factors that predict which
patients are likely to derive benefit in order to assist in the decision
making process.
PATIENTS AND METHODS
All women with advanced breast cancer attending the Breast Unit
at Guy's Hospital, London, UK, who were offered, and agreed to
undergo, first-line palliative chemotherapy between May 1990 and
June 1993 were eligible to participate in this study. In general, the
policy adopted within the unit is to manage asymptomatic
metastatic disease expectantly unless this is unacceptable to the
patient or unless problems are considered likely to arise in the near
future (e.g. some patients with lung metastases). Systemic therapy
is given to patients with disease which cannot be controlled by
local measures (e.g. radiotherapy, surgical excision, pleurodesis).
Chemotherapy is normally reserved for the treatment of disease
which can no longer be controlled by endocrine treatment, except
in cases of rapidly progressive disease when a response to
endocrine treatment is considered unlikely (e.g. lymphangitis
carcinomatosa or liver metastases with deranged hepatic function).
Several chemotherapy regimens were used for first-line treat-
ment during the study period, selection of which depended on the
patients' overall condition, her previous exposure to adjuvant
chemotherapy and on her agreement to participate in specific clin-
ical trials. Two phase II chemotherapy trials [using iododoxoru-
bicin (Twelves et al, 1994a) and vinorelbine (Twelves et al, 1994b)]
as first-line palliative chemotherapy were conducted in this period.
Patients with deranged liver function were normally treated with
single-agent epirubicin (given either weekly or 3 weekly). Outside
clinical trials, the preferred regimens were single-agent anthracy-
clines, cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
and methotrexate, mitomycin and mitozantrone (MMM). It was
planned that patients should receive six cycles ofchemotherapy, at
3- to 4- weekly intervals, unless disease progression or toxicity
prevented this. For those receiving weekly chemotherapy, the
planned duration of treatment was 18 weeks.
Each patient was informed about the proposed treatment by a
medical oncologist. This comprised an explanation of the nature
and extent of the patient's disease and how this related to her
symptoms, that there was a reasonable chance that chemotherapy
could control the disease, but not cure it, and the possible side-
effects from treatment and the measures to be taken to counteract
them. After the oncologist's explanation, the consent ofthe patient
to participate in the quality of life assessments was sought by the
study coordinator. Those who agreed to participate underwent
assessments on three occasions:
(i) pre-treatment - immediately before the first cycle oftreat-
ment;
(ii) intra-treatment - immediately before the third cycle of treat-
ment;
(iii) post treatment - at the first appointment after the last cycle of
treatment;
A self-report questionnaire, the Rotterdam Symptom Check List
(RSCL) (de Haes et al, 1990), was administered at all three assess-
ment points. A semistructured interview, developed specifically
for the study, was conducted after the completion of treatment.
Table 1 Patient characteristics (n = 155)
Number of patients (%)
Age
Median
Range
Marital status
Married
Single
Divorced
Widowed
Sites of disease
Soft tissue
Bone
Lung/pleura
Liver
Other
No. of sites of disease
1
2
3
4
Treatment
Epirubicin
Doxorubicin
lododoxorubicin
Vinorelbine
CMF
MMM
EFC
58 years
30-80
109 (70)
14 (9)
19 (12)
13 (8)
62 (54)
93 (60)
75 (48)
56 (36)
5 (3)
51 (33)
74 (48)
23 (15)
7 (5)
67 (43)
15 (10)
15 (10)
8 (5)
35 (23)
11 (7)
4 (3)
Table 2 Relationship between patient report of wellbeing and disease
response
Felt better Felt the same Felt worse 'Failures' Total
n 41 29 34 51 155
CR 4 2 6
PR 21 9 8 38
SD 8 10 9 27
PD 7 8 17 2 34
Death 39 39
N/A 1 10 11
The RSCL incorporates items on a range ofphysical symptoms.
Patients are asked to rate these items according to their experience
during the previous week. Each item is scored between 0 (not at
all) and 3 (very much). The RSCL also includes seven items
concerned with psychological symptoms: feeling worried, irri-
table, nervous, depressed, anxious, tense and despondent about the
future. These are scored on a similar four-point scale, and so
possible scores on this seven-item subscale range from 0 to 21. A
single item on functional status is rated 0 (up all day), 1 (up half
the day), 2 (up for short periods) and 3 (confined to bed).
The post-treatment interview included two questions about the
benefit of treatment. Patients were asked about their overall well-
being - 'How have you felt since just before starting treatment -
better, the same or worse?' They were encouraged to expand their
answer, which was recorded verbatim. Patients were also asked,
'How worthwhile do you feel treatment has been - very, moder-
ately, a little or not at all?' Again, patients were invited to expand
their response and their comments were recorded. An interview
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Table 3 Relationship between patient report of wellbeing and physical symptoms (% reporting 'moderately' or 'very much')
n Pretreatment % lntra-treatment % Post treatment % P-value
(pre vs post)
Been lacking energy
All patients
Better
Same
Worse
Fail
Been tired
All patients
Better
Same
Worse
Fail
Been in pain
All patients
Better
Same
Worse
Fail
Been short of breath
All patients
Better
Same
Worse
Fail
Been lacking appetite
All patients
Better
Same
Worse
Fail
Had a dry mouth
All patients
Better
Same
Worse
Fail
rather than a questionnaire format was adopted to elicit patients'
report of treatment benefit because these were novel measures and
the interviewer's probing, after asking the standard initial question
enabled clarification that the patient was answering the questions
according to their intended meanings. All the interviews were
conducted by the research nurse. A tape-recorded sample of the
interviews were listened to by a second researcher to check that the
interview format was standardized and there was no evidence of
bias in the interview approach.
Statistical methods
RSCL scores were summarized using their medians. Differences
between pretreatment RSCL scores across patients categorized
into four groups according to their post-treatment report of well-
being (see below) were examined using the Wilcoxon rank sum
test. Changes from pre- and post-treatment RSCL scores for each
ofthese four patient groups were examined using Friedman's two-
way ANOVA. Relationships between ordered categorical data
(e.g. patient report of wellbeing and disease response) were tested
for significance using the X2 distribution. Logistic regression
analyses were performed to identify possible predictive factors for
a patient's report of post-treatment wellbeing. Both forward and
backward methods were used.
RESULTS
First-line palliative chemotherapy was discussed with 163
patients, all of whom agreed to receive treatment during the study
period. A total of 160 patients started treatment. In the other three
cases, chemotherapy was withheld because of a good symptomatic
response to local measures (n = 2) or because of development of
cranial metastases (n = 1). Two patients received chemotherapy,
but declined to undergo the quality of life (QoL) assessments. In a
further three cases, quality of life assessments and the post-treat-
ment interviews were missed. These five patients have, therefore,
been excluded from the current analysis, which comprises a total
of 155 patients.
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51
45
62
37
34
62
0.02
0.39
0.61
155
41
29
34
51
155
41
29
34
51
155
41
29
34
51
155
41
29
34
51
155
41
29
34
51
155
41
29
34
51
46
55
74
24
24
29
27
24
44
62
71
31
53
78
60
66
34
65
67
50
49
34
53
57
42
41
24
35
57
37
32
28
29
53
32
20
7
35
55
49
31
74
12
21
47
22
21
35
0.02
0.48
0.73
0.01
0.58
0.73
0.27
0.46
0.73
24
31
32
27
24
24
0.61
0.58
0.65
34
38
41
32
24
53
0.64
0.49
0.09
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Figure 2 Relationship between patient report of pain and overall wellbeing
Patients and treatment characteristics are shown in Table 1. The
median duration ofchemotherapy was 14 weeks (range from 1 day
to 28 weeks). Sixty-two (40%) patients received the full planned
treatment, the other 93 patients having either died or discontinued
treatment early because of disease progression or toxicity. Six
(4%) patients achieved a complete remission and 38 (25%) a
partial response, giving an overall response rate of 44/155 (28%).
Eleven patients were not evaluable for response, giving a response
rate among evaluable patients of 44/144 (31%). A further 27
(17%) patients had stable disease.
Fifty-one (33%) ofthe 155 patients were not available for post-
treatment interview because of death during the treatment period
(n = 39), early progression ofdisease before the planned midpoint
assessment (n = 2) or because they discontinued treatment and
Table 4 Relationship between patient report of wellbeing and psychological
distress (median RSCL psychological subscale scores)
n Pretreatment Intra- Post P-value
treatment treatment
All patients 155 8
Better 41 8 3 3 < 0.0001
Same 29 6 4 3 0.13
Worse 34 9.5 7 8 0.16
Fail 51 9
stopped attending the unit (n = 10). One hundred and four patients
(67%) underwent all three QoL assessments including the post-
treatment interview. Forty-two of these patients had discontinued
treatment early (but after the midpoint assessment) because of
disease progression or toxicity. In 22 cases, the post-treatment
assessment was conducted shortly after patients had commenced
on second-line chemotherapy. However, no major differences
were observed between those who were interviewed after starting
second-line treatment and those who were being observed after
discontinuing first-line treatment early. The median time between
pretreatment assessment and the assessment before the third cycle
was 6 (range 3-11) weeks. The median time between the first day
of the last cycle and the post-treatment assessment was 4 (range
3-7) weeks.
As the main objective ofpalliative chemotherapy is to improve
quality oflife, the question about wellbeing was taken as the main
outcome measure for the study. Patients were categorized into four
groups as follows:
* those who felt better: n = 41 (26%);
* those who felt the same as before treatment: n = 29 (19%);
* those who felt worse: n = 34 (22%);
* those who were unavailable for post-treatment assessment -
'failures': n = 51 (33%).
For the purpose of this study, it was assumed that patients who
were unavailable for a post-treatment assessment could not have
benefited from treatment. The relationship between wellbeing as
assessed by the patients and conventional disease response
measurements is shown in Table 2. Among the 104 patients who
were fully assessed, a clear relationship was observed between
disease response and wellbeing (x2 = 17.1, P = 0.03).
PHYSICAL SYMPTOMS
The six most commonly reported physical symptoms and their
prevalence in the week before each assessment are shown for each
of the four outcome groups in Table 3. For each ofthese common
symptoms, the lowest pretreatment prevalence of symptoms was
among the group who reported feeling the same post treatment.
Lack of energy and tiredness were the commonest symptoms
before treatment, with over 60% ofpatients reporting moderate to
severe levels of each of these symptoms. Patients who reported
feeling better overall after treatment also reported significant
improvements in their lack of energy (P = 0.02), tiredness (P =
0.02) and pain (P = 0.01) over the course of treatment (Table 3,
Figures 1 and 2). No such improvements were found forthose who
felt the same or worse after treatment. Patients reports of well-
being after treatment were unrelated to changes in shortness of
breath, lack ofappetite and dry mouth (Table 3 and Figure 3).
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Table 5 Relationship between patient report of wellbeing and functional
status (proportions up for short periods or confined to bed)
n Pretreatment Intra- Post P-value
% treatment % treatment % (pre vs post)
All patients 155 19
Better 41 20 20 5 0.07
Same 29 3 17 10 0.61
Worse 34 15 12 15 1.0
Fail 51 31
Table 6 Relationship between patient report of wellbeing and patient report
of the worthwhileness of treatment
Worthwhile
Wellbeing Very Moderately A little Not at all
Better 25 5 8 3
Same 7 7 7 8
Worse 4 4 5 21
Total 36 16 20 32
PSYCHOLOGICAL SYMPTOMS
The RSCL psychological subscale scores at each assessment for
the four outcome groups are shown in Table 4. The pretreatment
levels of psychological distress across the four outcome groups
were significantly different (P = 0.03). Patients who reported
feeling better overall after treatment also reported a significant
decrease in psychological distress. No such improvement in
distress was seen for patients who felt the same or worse after
treatment.
Functional status
The relationship between patient report of wellbeing and func-
tional status is shown in Table 5. The pretreatment levels of func-
tional impairment across the four outcome groups is significantly
different (P = 0.02). The proportion ofthose patients getting up for
short periods or confined to bed decreased during treatment for
those who reported feeling better after treatment, but not signifi-
cantly. There was no improvement in functional status for those
patients who reported feeling the same or worse after treatment.
Worthwhileness
Half of the patients who were interviewed reported that they felt
treatment had been moderately or very worthwhile, which repre-
sents one-third of all the patients who started treatment. Patients'
view ofthe worthwhileness of treatment was associated with their
report of wellbeing after treatment (%2 = 35.1, P < 0.0001) (Table
6). Twenty-five out of 104 (24%) patients who were interviewed
post treatment reported feeling better andjudged treatment as very
worthwhile.
Example
Response to worthwhileness question:
'Its been very worthwhile - I am like a new woman. I'd
definitely do it again.'
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Figure 3 Relationship between patient report of shortness of breath and
overall general wellbeing
Response to wellbeing question:
'Before starting treatment, I felt like a whipped dog. Now
I've got my mobility and independence. My quality oflife is
much improved.'
There were, however, 13 out of 104 (13%) patients who reported
that the treatment was at least a little worthwhile, despite feeling
worse than they did before treatment.
Example
Response to worthwhileness question:
'Had to try it - you have to don't you? I don't think it's done
much for me though - perhaps I've had more time because of
it, I don't know. Ifthe doctors suggest it, it must be for a
reason - you have it anyway.'
Response to wellbeing question:
'Much worse. I can't get about any more, because I have so
much pain.'
Wellbeing, worthwhileness and toxicity
The relationships between patient reports ofwellbeing and worth-
whileness at post-treatment interview and treatment toxicity have
been examined. Patients' reports of nausea, vomiting and mouth
problems on the RSCL at the midpoint ofchemotherapy were used
as markers of toxicity, as for each of these items the pretreatment
incidence of moderate/severe problems was low among patients
who subsequently completed a post-treatment interview and rose
during the course of chemotherapy. The patients' reports of hair
loss at the completion oftreatment was used as a further marker of
toxicity. No significant associations were found between these
patient-rated markers oftreatment toxicity and either wellbeing or
worthwhileness after treatment.
Factors predicting post-treatment wellbeing
Logistic regression analyses were undertaken to examine which
pretreatment factors predicted patient report of post-treatment
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wellbeing. The factors included: sites of disease, number of sites of
disease, pretreatment RSCL psychological, functional and physical
(lacking energy, tiredness, pain, breathlessness, dry mouth and
lacking appetite) scores. No factors were identified which predicted
patients who subsequently felt better (n = 41), as opposed to those
who subsequently felt the same or worse or who failed to reach the
post-treatment interview (n = 114) according to logistic regression
analysis. However, the presence of a dry mouth (P = 0.003) and
high levels of psychological distress (P = 0.03) predicted feeling
worse or failing (n = 75) as opposed to feeling better or the same
(n = 80). Lacking energy (P = 0.01), the presence of a dry mouth
(P = 0.02), of liver metastases (P = 0.03) and breathlessness
(P = 0.03) predicted failing to reach the post-treatment interview
(n = 51) as opposed to the other patient outcomes (n = 104).
Further logistic regression analyses were undertaken to examine
whether any changes in quality of life scores between the pre- and
intra-treatment assessments predicted post-treatment wellbeing.
These analyses were based on 123 patients, 32 having failed to
reach the second assessment. The factors examined included
changes in RSCL scores for lacking energy, tiredness, pain, breath-
lessness, lacking appetite, having a dry mouth, functional status
and psychological distress. Changes in tiredness (P = 0.002) and
breathlessness (P = 0.06) predicted patients who subsequently felt
better (n = 41), as opposed to those who felt the same, worse or
who failed (n=82).
DISCUSSION
The combined complete and partial response rate in this study of
31% of evaluable cases, is low compared with the 40-60%
frequently reported for patients entered into phase III trials
(Macauley and Smith, 1986) including those conducted in this unit
(Steiner et al, 1983; Richards et al, 1992). It is, nevertheless, in line
with the response rate of 34% to first-line chemotherapy reported
in an unselected series attending this unit (Gregory et al, 1993).
This supports the view that the extent of the benefit of first-line
palliative chemotherapy, in terms of disease response, demon-
strated in clinical trials is unlikely to apply to the totality of
patients with advanced breast cancer receiving such treatment.
This study has demonstrated a clear relationship between
disease response and patients' report of overall wellbeing after
treatment, but the correlation is not exact. Whereas 61% of
patients who reported feeling better had a disease response, 17% of
those feeling better had progressive disease and 24% of those
feeling worse had a partial response. It would seem, therefore, that
although the disease model of advanced breast cancer explains a
good deal of patient wellbeing, it does not explain all of it. The
finding of a relationship between disease response and wellbeing
is in line with other studies in advanced breast cancer, which have
shown that the quality of life of patients is improved by achieving
tumour response (Baum et al, 1980; Coates et al, 1987). Similar
results have been reported in patients with other advanced forms of
cancer, including small-cell lung cancer (Coates et al, 1983), non-
small-cell lung cancer (Kaasa et al, 1988) and colorectal cancer
(Glimelius et al, 1989).
The main assessment of outcome used in this study is a novel
measure of overall patient wellbeing after treatment. Whereas it is
recognized that for many clinical and research applications quality
of life is optimally defined and assessed in terms of its component
parts, a global assessment has utility in that it may capture
information not covered by the more specific items and it might
facilitate incorporating psychosocial variables into formal medical
decision-making models, e.g. quality-adjusted life-year analysis.
It may also be useful in assessing the relative value attached to
specific items or domains. The findings of this study suggest that
feeling better after treatment with first-line palliative chemo-
therapy is associated with improvements in psychological distress,
tiredness, lack of energy and pain.
Patients' perception of the worthwhileness of treatment was
correlated with their report of wellbeing after chemotherapy, but
not entirely so. As well as being related to improvement in quality
of life, patients' views of worthwhileness may also reflect the hope
that treatment brings. The provision of hope is one aspect of care
that is rarely critically evaluated by doctors, being considered
more of a philosophical than a medical issue (Slevin 1992).
However, in a study based on hypothetical treatment scenarios,
patients with cancer who were about to undergo chemotherapy
were asked to balance the price they would be prepared to pay in
terms of side-effects for a particular degree of benefit. About half
of patients reported they would accept intensive toxic chemo-
therapy for minimal benefit in terms of survival, prolongation of
life or relief of symptoms (Slevin et al, 1990).
This is a hypothesis-generating study. There is preliminary
evidence for the psychometric validity of the novel measure of
overall patient wellbeing after treatment. The convergent validity
of the measure, in this context, is demonstrated by the significant
correlations between patients' report of feeling better and
improvements in scores on a number of items/subscales of the
RSCL. Similarly, the construct validity of the measure, in this
context, is demonstrated by the significant correlation between
feeling better and disease response. The approach to the assess-
ment of benefit from palliative chemotherapy adopted in this study
now needs further validation in a larger cohort of women with
advanced breast cancer. If the study findings are confirmed, this
would suggest that palliative chemotherapy confers benefit on a
substantial proportion of patients with advanced breast cancer,
with about a quarter feeling better after treatment and nearly a half
feeling better or the same some 4-6 months after the start of treat-
ment. The value to the patient offeeling the same after treatment is
difficult to assess within the observational design of this study. The
data indicate that those who reported feeling the same were on
average less symptomatic at the start of chemotherapy. Clearly, it
is more difficult for a patient to improve if they start out feeling
relatively well. Nevertheless, for this group avoidance of deterio-
ration may be beneficial. Theoretically, a randomized controlled
trial might offer the study design within which to examine this
issue, however the ethical and emotional objections to such a study
would be likely to preclude its viability.
The study findings suggest that particular quality of life para-
meters can be identified which may assist clinicians in deciding
which patients should not be offered treatment because ofhigh risk
of 'failure', and whether to stop treatment at midpoint because ofa
low chance of benefit. Other relevant predictive factors may be
revealed from analysis of a larger cohort. If this approach is
demonstrated to be robust in the assessment of palliative
chemotherapy for advanced breast cancer, it may have wider appli-
cation in the assessment of chemotherapy for other common
cancer types and, thereby, help to inform not only individual
clinical decision making but also resource allocation in a costly
aspect ofcancer care.
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